IsoPlexis (NASDAQ:ISO) Lowered to “Hold” at Zacks Investment Research

IsoPlexis (NASDAQ:ISOGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, Zacks.com reports.

According to Zacks, “IsoPlexis Corporation is a life science technology company which build solutions for development of curative medicines and personalized therapeutics. IsoPlexis Corporation is based in BRANFORD, Conn. “

Several other research firms have also commented on ISO. Morgan Stanley decreased their target price on shares of IsoPlexis from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Tuesday, February 15th. SVB Leerink decreased their target price on shares of IsoPlexis from $20.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, January 27th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, IsoPlexis currently has an average rating of “Buy” and a consensus price target of $13.31.

IsoPlexis stock traded down $0.12 during midday trading on Friday, hitting $1.99. The company’s stock had a trading volume of 67,686 shares, compared to its average volume of 89,382. IsoPlexis has a 1-year low of $1.62 and a 1-year high of $16.95. The company has a debt-to-equity ratio of 0.34, a current ratio of 7.78 and a quick ratio of 5.85. The company has a 50-day moving average price of $2.59 and a two-hundred day moving average price of $6.01.

IsoPlexis (NASDAQ:ISOGet Rating) last released its earnings results on Wednesday, May 11th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Analysts forecast that IsoPlexis will post -1.97 EPS for the current year.

Several institutional investors have recently made changes to their positions in the stock. Citigroup Inc. bought a new stake in shares of IsoPlexis during the 4th quarter valued at approximately $36,000. California State Teachers Retirement System bought a new stake in IsoPlexis during the 4th quarter worth approximately $43,000. Deutsche Bank AG bought a new stake in IsoPlexis during the 4th quarter worth approximately $47,000. Wells Fargo & Company MN bought a new stake in IsoPlexis during the 4th quarter worth approximately $48,000. Finally, JPMorgan Chase & Co. bought a new stake in IsoPlexis during the 4th quarter worth approximately $51,000. 76.49% of the stock is currently owned by institutional investors.

About IsoPlexis (Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea.

Featured Stories

Get a free copy of the Zacks research report on IsoPlexis (ISO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.